P. Aranda

发表

Prevalence and Factors Associated With Circadian Blood Pressure Patterns in Hypertensive Patients

G. Parati, J. Banegas, L. Ruilope, 2009, Hypertension.

Hipertensión arterial y polı́tica de salud en España Hypertension and health policy in Spain

J. Banegas, L. Ruilope, J. Segura, 2009 .

Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.

L. Ruilope, J. Segura, P. Aranda, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Influence of Gender and Genetic Variability on Plasma Angiotensin Peptides

M. Gaitán, C. Ferrario, P. Aranda, 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease

J. Górriz, A. Martínez‐Castelao, J. Portolés, 2013, BMC Nephrology.

A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease

L. Ruilope, J. Segura, P. Aljama, 2001, Journal of hypertension.

Renin-angiotensin system dual blockade using angiotensin receptor plus aliskiren decreases severe proteinuria in kidney transplant recipients.

V. López, M. Cabello, E. Sola, 2010, Transplantation proceedings.

Comparison of losartan and amlodipine in renally impaired hypertensive patients.

P. Zucchelli, P. Aranda, B. Iversen, 1998, Kidney international. Supplement.

SureClick® (Darbepoetin alfa) can improve perceived satisfaction and competence for anemia treatment and increase self-administration in non-dialyzed patients with chronic kidney disease.

X. Bonafont, P. Aranda, J. Claverol, 2013, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Diuretics and the treatment of systemic hypertension.

P. Aranda, E. López de Novales, 1990, The American journal of cardiology.

Long-term renoprotective effects of usual versus high dose of telmisartan in non-diabetic nephropathies

L. Ruilope, P. Aranda, M. Frutos, 2004 .

Cholesterol levels in untreated Spanish hypertensive patients

J. Banegas, J. Rodicio, P. Aranda, 1999 .

Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study.

L. Ruilope, A. Coca, Á. Gil de Miguel, 2004, American journal of hypertension.

[Evaluation and management of hypertension in Spain. A consensus guide].

J. Banegas, L. Ruilope, A. de la Sierra, 2008, Medicina clinica.

Role of dihydropyridinic calcium channel blockers in the management of hypertension

J. Redón, V. Barrios, A. Coca, 2013, Expert review of cardiovascular therapy.

Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study

Seville, Vizcaya, J. Bobes, 2012, European Psychiatry.

Surgical Menopause Increases Salt Sensitivity of Blood Pressure

L. Raij, P. Aranda, I. Schulman, 2006, Hypertension.

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study

J. Bobes, C. Arango, J. Rejas, 2007, Schizophrenia Research.

Prevalence of Atherogenic Dyslipidemia in Spanish Hypertensive Patients and Its Relationship With Blood Pressure Control and Silent Organ Damage.

A. de la Sierra, M. Gorostidi, X. Pintó, 2015, Revista espanola de cardiologia.

Discrepancies between office and ambulatory blood pressure: clinical implications.

F. Rodríguez‐Artalejo, J. Banegas, L. Ruilope, 2009, The American journal of medicine.

A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs.

J. Darbà, L. Kaskens, J. Bobes, 2013, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study

J. Bobes, C. Arango, J. Rejas, 2008, Schizophrenia Research.

Effect of antihypertensive treatment on progression of renal insufficiency in non-diabetics patients. (Espiral trial)

L. Ruilope, P. Aljama, P. Aranda, 1995 .

Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study

J. Bobes, C. Arango, J. Rejas, 2008, Schizophrenia Research.

Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes

J. Banegas, L. Ruilope, E. Vinyoles, 2011, Hypertension Research.

Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study

L. Ruilope, M. Gorostidi, M. Praga, 2006, Journal of hypertension.

Factors associated with therapeutic inertia in hypertension: validation of a predictive model

J. Redón, A. Coca, P. Lázaro, 2010, Journal of Hypertension.

Response to Surgical Menopause, Salt Sensitivity, and NO Bioavailability in Women

L. Raij, P. Aranda, I. Schulman, 2006 .

Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease.

L. Ruilope, M. Gorostidi, J. Segura, 2014, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

Perception of health and understanding of cardiovascular risk among patients with recently diagnosed diabetes and/or metabolic syndrome

J. J. de la Cruz, N. Martell-Clarós, C. Campo, 2013, European journal of preventive cardiology.

[Strategies for effective control of arterial hypertension in Spain. Consensus document].

L. Rodríguez-Mañas, E. Esmatjes, A. Coca, 2006, Revista clinica espanola.